CA
NZ
UK
AU
IND
US
Kodiak Sciences (NASDAQ:KOD) more than doubled on Monday, September 28 after two experimental eye drugs hit their goals in a pivotal Phase 3 trial, turning a small biotech into the day's biggest story on a down day for Wall Street.
While chipmakers and software stocks sank on Monday, September 28, biotech delivered a string of eye-popping gains, led by Kodiak Sciences (NASDAQ:KOD), aTakeoverof Lifecore Biomedical (NASDAQ:LFCR) and a batch of deals and analyst calls.
● Lakewood-Amedex Biotherapeutics (LABT) closed at $1.15 on Monday, down 31.14% from $1.67, after a reported premarket gain.
Health care was one of only three S&P 500 sectors to finish higher on Monday, September 28, on a day that brought an upgrade for Teleflex (NYSE:TFX), a big licensing deal at Merck (NYSE:MRK) and a blockbuster session for biotech.
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT), a penny stock, closed down 31.14% at $1.15 on Monday, September 28, 2026. The clinical-stage biotech recently listed on Nasdaq and has been advancing its Nu-3 program.
Kodiak Sciences (NASDAQ:KOD) closed up 177.96% at $89.92 on Monday, September 28, 2026. The clinical-stage retinal disease company reported positive topline results from its pivotal Phase 3 DAYBREAK study.
● Onconetix (ONCO) traded near $1.20, up about 16.5%, at 1:06 p.m. Eastern on Monday, according to a movers list.
● SL Science Holding (SLBT) closed at $1.93 on Monday, up 22.93% from $1.57, one of the Nasdaq's notable risers.
● YD Bio is a Taiwan-based biotech company working on methylation-based cancer diagnostics, and its shares trade on the Nasdaq.
Definium Therapeutics (NASDAQ:DFTX) was among the gainers in US markets on Monday, September 28, 2026, closing the session up 6.19% at $38.41. The company is a clinical-stage biotechnology company that is relatively recently public and lightly followed.
Please wait processing your request...